(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 January 2010 (07.01.2010)

PCT

(10) International Publication Number
WO 2010/003118 A1

(51) International Patent Classification:
*C12N 15/62* (2006.01) *C07K 16/24* (2006.01)
*C07K 14/715* (2006.01) *A61K 38/17* (2006.01)
*C07K 16/28* (2006.01)

(21) International Application Number:
PCT/US2009/049616

(22) International Filing Date:
2 July 2009 (02.07.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

| | | |
|---|---|---|
| 61/134,091 | 2 July 2008 (02.07.2008) | US |
| 61/134,090 | 2 July 2008 (02.07.2008) | US |
| 61/134,089 | 2 July 2008 (02.07.2008) | US |
| 61/134,088 | 2 July 2008 (02.07.2008) | US |
| 61/134,085 | 2 July 2008 (02.07.2008) | US |
| 61/134,087 | 2 July 2008 (02.07.2008) | US |
| 61/134,086 | 2 July 2008 (02.07.2008) | US |
| 61/181,232 | 26 May 2009 (26.05.2009) | US |

(71) Applicant *(for all designated States except US)*: **TRUBION PHARMACEUTICALS, INC.** [US/US]; 2401 Fourth Avenue, Suite 1050, Seattle, WA 98121 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LOFQUIST, Alan, Keith** [US/US]; 9422 N.e. 130th Place, Kirkland, WA 98034 (US). **BAUM, Peter, Robert** [US/US]; 6027 - 34th Avenue N.e., Seattle, WA 98115 (US). **THOMPSON, Peter, Armstrong** [US/US]; 14075 N.e. 30th Place, Bellevue, WA 98007 (US). **MISHER, Lynda** [US/US]; 10614 - 10th Place N.e., Seattle, WA 98125 (US).

(74) Agents: **SLEATH, Janet** et al.; Speckman Law Group PLLC, 1201 Third Avenue, Suite 3, Seattle, WA 98101 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17**:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published**:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: TGF-B ANTAGONIST MULTI-TARGET BINDING PROTEINS

(57) **Abstract**: This disclosure provides a multi-target fusion protein composed of a TGF? antagonist domain and another binding domain antagonistic for a heterologous target (such as IL6, IL10, VEGF, TNF, HGF, TWEAK, IGF) or agonistic for a heterologous target (such as GITR). The multi-specific fusion protein may also include an intervening domain that separates the binding domains and allows for dimerization. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

WO 2010/003118 A1